Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-205: pemigatinib with or without pembrolizumab versus standard of care as first-line treatment for FGFR3-altered advanced urothelial carcinoma in cisplatin-ineligible patients
MOH_2020-05-10_008926Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemigatinib, pembrolizumab, gemcitabine and carboplatin in transitional cell carcinoma (TCC) (3 cohorts), sponsored by Incyte. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2020-05-10_008926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-10_008926.